ストックスクリーナーアプリを入手
8.56
0.59%
0.05
プレマーケット:
8.73
0.17
+1.99%
前日終値:
$8.51
開ける：
$8.51
24時間の取引高:
281.67K
Relative Volume:
0.68
時価総額：
$445.78M
収益：
-
当期純損益:
$-19.90M
株価収益率:
-16.15
EPS:
-0.53
ネットキャッシュフロー:
$-19.80M
1週間 パフォーマンス:
-6.14%
1か月 パフォーマンス:
+27.57%
6か月 パフォーマンス:
+103.81%
1年 パフォーマンス:
+57.06%
1日の値動き範囲:
$7.97
$8.88
1週間の範囲:
$7.76
$9.1599
52週間の値動き範囲:
$3.19
$9.23
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
名前
Diamedica Therapeutics Inc
セクター
電話
(763) 496-5454
住所
301 CARLSON PARKWAY, MINNEAPOLIS, MN
DMAC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
8.56 | 443.18M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-14 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-10-30 | 開始されました | TD Cowen | Buy |
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-06-22 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 開始されました | Oppenheimer | Outperform |
| 2021-02-17 | 開始されました | ROTH Capital | Buy |
| 2020-10-30 | 開始されました | Guggenheim | Buy |
| 2020-07-08 | 開始されました | Maxim Group | Buy |
| 2019-04-30 | 開始されました | Dougherty & Company | Buy |
| 2019-03-05 | 開始されました | Lake Street | Buy |
すべてを表示
Diamedica Therapeutics Inc (DMAC) 最新ニュース
What dividend safety score for DiaMedica Therapeutics Inc. stock2025 Risk Factors & Fast Gain Stock Tips - Newser
What drives DiaMedica Therapeutics Inc stock priceAnalyst Downgrades & Free Lightning Fast Capital Gains - earlytimes.in
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth - Yahoo Finance
Is DiaMedica Therapeutics Inc. stock in correction or buying zoneJuly 2025 Patterns & Fast Exit and Entry Trade Guides - BỘ NỘI VỤ
Private Capital's DiaMedica Therapeutics Inc(DMAC) Holding History - GuruFocus
Why DiaMedica Therapeutics Inc. stock is a value investor pickJuly 2025 Drop Watch & Smart Allocation Stock Tips - BỘ NỘI VỤ
There is no way DiaMedica Therapeutics Inc (DMAC) can keep these numbers up - Setenews
Dir Parsons Acquires 12,000 Of DiaMedica Therapeutics Inc [DMAC] - TradingView
[Form 4] DiaMedica Therapeutics Inc. Insider Trading Activity - Stock Titan
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
DiaMedica In Focus After 52-Week High And FDA Meeting Progress - RTTNews
How DiaMedica Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Intraday Action & Verified Swing Trading Watchlists - newser.com
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double - inkl
HC Wainwright Has Bearish Forecast for DMAC FY2025 Earnings - Defense World
Smart tools for monitoring DiaMedica Therapeutics Inc.’s price actionPortfolio Value Summary & Growth Focused Stock Pick Reports - newser.com
Why analysts remain bullish on DiaMedica Therapeutics Inc. stock2025 Top Gainers & Fast Gaining Stock Reports - newser.com
Published on: 2025-11-19 22:42:15 - newser.com
Will DiaMedica Therapeutics Inc. stock return to pre crisis levels2025 Analyst Calls & Momentum Based Trading Signals - newser.com
Published on: 2025-11-19 13:58:17 - newser.com
Is DiaMedica Therapeutics Inc. stock supported by innovation pipelineTake Profit & Fast Momentum Entry Tips - newser.com
This trade activity should not be overlooked: DiaMedica Therapeutics Inc (DMAC) - Setenews
Is DiaMedica Therapeutics Inc. still worth holding after the dip2025 Institutional Moves & Weekly Breakout Opportunity Watchlist - newser.com
What is HC Wainwright’s Estimate for DMAC Q1 Earnings? - Defense World
Published on: 2025-11-18 23:37:26 - newser.com
Can DiaMedica Therapeutics Inc. stock outperform in 2025 bull marketTrade Entry Summary & Fast Gaining Stock Strategy Reports - newser.com
Why DiaMedica Therapeutics Inc. stock remains on watchlistsRate Hike & Safe Swing Trade Setups - newser.com
Short interest data insights for DiaMedica Therapeutics Inc.2025 Biggest Moves & AI Powered Buy/Sell Recommendations - newser.com
DMAC News Today | Why did DiaMedica Therapeutics stock go up today? - MarketBeat
Has DiaMedica Therapeutics Inc. formed a bullish divergence2025 Price Momentum & Community Driven Trade Alerts - newser.com
Developing predictive dashboards with DiaMedica Therapeutics Inc. dataStop Loss & Fast Momentum Entry Tips - newser.com
DiaMedica Therapeutics Inc Stock Analysis and ForecastSector-Based Investing & Low Risk Trading Growth - earlytimes.in
What Futures Contracts Reveal About Globesecure Technologies Limiteds Near Term VolatilityUtilities Sector Analysis & Small Budget Investment Tips - earlytimes.in
Can DiaMedica Therapeutics Inc. stock double in next 5 yearsCEO Change & Stock Market Timing Techniques - newser.com
DiaMedica Therapeutics Reports Q3 2025 Financial Results - MSN
Lake Street Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC) - The Globe and Mail
DiaMedica Therapeutics (NASDAQ:DMAC) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Cantor Fitzgerald Initiates Coverage of DiaMedica Therapeutics (DMAC) with Overweight Recommendation - MSN
Visual analytics tools that track DiaMedica Therapeutics Inc. performanceJuly 2025 Breakouts & Reliable Price Breakout Alerts - newser.com
Using flow based indicators on DiaMedica Therapeutics Inc.Exit Point & Consistent Return Investment Signals - newser.com
Backtesting results for DiaMedica Therapeutics Inc. trading strategies2025 AllTime Highs & Daily Volume Surge Trade Alerts - newser.com
DMAC: Cantor Fitzgerald Initiates Coverage with Overweight Ratin - GuruFocus
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2025 Earnings Call Transcript - Insider Monkey
Diamedica Therapeutics Inc (DMAC) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
1.10%
大文字化:
|
ボリューム (24 時間):